Cellex Patient Treatment GmbH   Report issue

For profit Phase 1
Founded: Dresden Germany (2014)

Organization Overview

First Clinical Trial
2020
NCT04230265
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Cellex Patient Treatment GmbH

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Disease Progression (Phase 1)

Kidney Neoplasms (Phase 1)

Leukemia (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 5